Hudson Bay Capital Management LP Purchases New Stake in MBX Biosciences, Inc. $MBX

Hudson Bay Capital Management LP bought a new position in MBX Biosciences, Inc. (NASDAQ:MBX) in the third quarter, according to its most recent disclosure with the SEC. The firm bought 85,000 shares of the company’s stock, valued at approximately $1,488,000. Hudson Bay Capital Management LP owned about 0.19% of MBX Biosciences as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Russell Investments Group Ltd. raised its position in MBX Biosciences by 4,131.4% in the third quarter. Russell Investments Group Ltd. now owns 1,481 shares of the company’s stock valued at $26,000 after purchasing an additional 1,446 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of MBX Biosciences by 117.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,896 shares of the company’s stock worth $51,000 after acquiring an additional 1,567 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of MBX Biosciences in the 3rd quarter worth approximately $88,000. Virtus Investment Advisers LLC boosted its position in shares of MBX Biosciences by 9.6% during the 2nd quarter. Virtus Investment Advisers LLC now owns 8,772 shares of the company’s stock worth $100,000 after purchasing an additional 766 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in MBX Biosciences by 40.3% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,329 shares of the company’s stock valued at $106,000 after purchasing an additional 2,682 shares during the last quarter.

MBX Biosciences Stock Up 0.9%

Shares of NASDAQ:MBX opened at $28.68 on Monday. MBX Biosciences, Inc. has a 52 week low of $4.81 and a 52 week high of $44.89. The company has a 50-day moving average price of $35.42 and a 200 day moving average price of $27.20. The company has a market cap of $1.36 billion, a P/E ratio of -11.90 and a beta of 1.06.

MBX Biosciences (NASDAQ:MBX) last issued its earnings results on Thursday, March 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.15.

Insiders Place Their Bets

In other news, CEO P. Kent Hawryluk acquired 18,500 shares of MBX Biosciences stock in a transaction that occurred on Friday, March 13th. The stock was purchased at an average cost of $28.41 per share, with a total value of $525,585.00. Following the completion of the acquisition, the chief executive officer owned 486,777 shares in the company, valued at $13,829,334.57. This trade represents a 3.95% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 52.19% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Barclays initiated coverage on MBX Biosciences in a research note on Tuesday, January 27th. They set an “overweight” rating and a $66.00 price target on the stock. Wall Street Zen raised MBX Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, December 21st. Stifel Nicolaus raised their target price on MBX Biosciences from $45.00 to $50.00 and gave the company a “buy” rating in a report on Friday, December 19th. Guggenheim boosted their price target on shares of MBX Biosciences from $77.00 to $88.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Finally, The Goldman Sachs Group initiated coverage on shares of MBX Biosciences in a research report on Thursday, December 4th. They set a “sell” rating and a $18.00 price target on the stock. Ten research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, MBX Biosciences presently has an average rating of “Moderate Buy” and an average price target of $51.56.

MBX Biosciences Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.